NVE Pharmaceuticals, an aggressive and high-profile manufacturer of energy and weight loss products, has transitioned to the post-ephedra era without suffering major blows to sales or profitability, according to Vice President of Marketing Karen Sinocchio. While sales data from IRI showed significant declines in NVE’s sales of its core Stacker products in mass market, Sinocchio said 2004 was “rock solid,” with growth in energy drinks and private label manufacturing.<
All access premium subscription
This content requires a subscription to Nutrition Business Journal.
As an NBJ subscriber, you receive 10 issues a year and access to the exclusive “NBJ subscriber only” content on newhope.com (excludes three-month subscriptions), which includes PowerPoint presentations, select data charts and archived articles. Subscribers also receive a 10 percent discount on data charts, comprehensive market research reports and webinars.
Email [email protected] for more information about subscribing.